Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Dose-escalated hypofractionated IMRT for localized prostate cancer has similar side effects when compared to conventional IMRT


Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study published in the April 1, 2014 edition of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).  

Previous randomized clinical trials have shown that dose-escalated radiation therapy improves prostate cancer control compared to lower-dose conventional radiation therapy. Conventional fractionation of dose-escalated radiation therapy (1.8 or 2 Gy fractions) can take up to nine weeks to complete, while hypofractionated radiation therapy can deliver a higher biologically effective dose over a shorter period of time (six weeks) and has the potential to increase prostate cancer control without increasing toxicity.

However, there are limited data on the late toxicity of moderate hypofractionated regimens for prostate cancer. This randomized trial from the University of Texas MD Anderson Cancer Center compares the late toxicity outcomes of men with localized prostate cancer treated with either conventionally fractionated IMRT (CIMRT) or dose-escalated hypofractionated IMRT (HIMRT).

Men with organ-confined prostate cancer were enrolled in this institutional review board-approved trial from January 2001 to January 2010 and were randomized to receive either CIMRT (75.6 Gy in 1.8 Gy fractions over eight-and-a-half weeks) or HIMRT (72 Gy in 2.4 Gy fractions over six weeks). Eligible patients had biopsy-proven prostate adenocarcinoma; good performance status; stage T1b-T3b disease; a prostate-specific antigen (PSA) ≤20 ng/ml; a Gleason score <10; and no clinical, radiographic or pathologic evidence of nodal or bone metastasis.

... more about:
»IMRT »PSA »Radiation »prostate »therapy »toxicity

Patients with stage cT3c or cT4 disease, a history of prior pelvic radiation therapy, or who received more than four months of hormone ablation therapy with prior or planned radical prostate surgery and with concurrent active malignancy other than nonmetastatic skin cancer or early-stage chronic lymphocytic leukemia were not eligible for the trial. The median age of the patient cohort was 68. Of the 203 patients analyzed in the study, 72 percent had stage T1 disease (146) and 89 percent had a PSA <10 ng/ml (181). Thirty-four percent (70) had Gleason 6 disease, 65 percent (131) had Gleason 7 disease and 1 percent (2) had Gleason 8 disease. Patients were classified into low-risk (28 percent = 57), intermediate risk (71 percent = 144) and high-risk (1 percent = 2) disease using current National Comprehensive Cancer Network risk-group definitions.

All patients were treated with static-field IMRT. One hundred and one (101) men received CIMRT and 102 men received HIMRT. Physician-reported toxicity was evaluated for all patients during treatment and at each follow-up visit. After completion of radiation therapy, follow-up was conducted at least every six months for the first two years post-treatment, and annually thereafter. Median follow-up was six years.

Late gastrointestinal (GI) and genitourinary (GU) toxicity were analyzed in this study, starting 90 days post-treatment, using modified Radiation Therapy Oncology Group toxicity grading. In the CIMRT arm, 17 percent (17) experienced grade 1 GI toxicity, 4 percent (4) experienced grade 2 GI toxicity and 1 percent (1) experienced grade 3 GI toxicity. In the HIMRT arm, 26 percent (27) experienced grade 1 GI toxicity, 9 percent (9) experienced grade 2 GI toxicity and 2 percent (2) experienced grade 3 GI toxicity. There was a numeric increase in the absolute frequency of late GI toxicity for men treated with HIMRT, but the difference was not statistically significant. The five-year actuarial grade 2 or 3 late GI toxicity was 5.1 percent (95 percent Confidence Interval (CI)) for patients treated with CIMRT and 10 percent for patients treated with HIMRT. The increase in late GI toxicity for men receiving HIMRT was the result of moderate and high radiation dose to a larger proportion of the rectum, which suggests that more stringent dose constraints for the rectum may result in lower late GI toxicity for those patients.

Additionally, there was not a statistically significant difference in the absolute frequency of late GU toxicity in men treated with CIMRT or HIMRT. In the CIMRT arm, 15 percent (15) experienced grade 1 GU toxicity, 14 percent (14) experienced grade 2 GU toxicity and 1 percent (1) experienced grade 3 GU toxicity. In the HIMRT arm, 10 percent (10) experienced grade 1 GU toxicity and 15 percent (15) experienced grade 2 GU toxicity; no patients reported grade 3 GU toxicity. The five-year actuarial grade 2 or 3 late GU toxicity was 16.5 percent (95 percent CI) for patients treated with CIMRT and 15.8 percent for patients treated with HIMRT.

“These results demonstrate that the length of radiation treatment for prostate cancer can be safely decreased to six weeks (from eight-and-a-half weeks) by delivering larger daily doses of radiation without increasing the urinary and bowel effects,” said Karen E. Hoffman, MD, a co-author of the study and assistant professor in the Division of Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston. “Decreasing the length of treatment decreases the cost and is more convenient for patients.”

For a copy of the manuscript of the study, contact Brittany Ashcroft at 703-839-7336. Learn more about the Red Journal.

Brittany Ashcroft | EurekAlert!

Further reports about: IMRT PSA Radiation prostate therapy toxicity

More articles from Physics and Astronomy:

nachricht Sharpening the X-ray view of the nanocosm
23.03.2018 | Changchun Institute of Optics, Fine Mechanics and Physics

nachricht Drug or duplicate?
23.03.2018 | Fraunhofer-Institut für Angewandte Festkörperphysik IAF

All articles from Physics and Astronomy >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>